Media & Investors

Press Releases

Date Title Media
12/05/17
Summary ToggleUpdated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium
11/07/17
Summary ToggleInitial Results from Phase 2 Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting
11/02/17
Summary ToggleCalithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights
10/19/17
Summary ToggleCalithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda
10/03/17
Summary ToggleCalithera Biosciences Announces Appointment of Sumita Ray as General Counsel
09/21/17
Summary ToggleCalithera Biosciences Appoints Blake Wise to Board of Directors
09/20/17
Summary ToggleCalithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-Oncology Roundtable
09/19/17
Summary ToggleCalithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
08/30/17
Summary ToggleCalithera Biosciences to Participate in the Citi 12th Annual Biotech Conference and the Wells Fargo Healthcare Conference
08/08/17
Summary ToggleCalithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights
08/07/17
Summary ToggleCalithera Biosciences Initiates a Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell Carcinoma
08/02/17
Summary ToggleCalithera Biosciences to Report Second Quarter 2017 Financial Results on Tuesday, August 8, 2017
06/14/17
Summary ToggleCalithera Biosciences to Participate in the JMP Securities 2017 Life Sciences Conference
06/07/17
Summary ToggleCalithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 for Treatment of Patients with Renal Cell Carcinoma
06/05/17
Summary ToggleCB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting
05/10/17
Summary ToggleBristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma
05/09/17
Summary ToggleCalithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights
05/03/17
Summary ToggleCalithera Biosciences to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017
04/20/17
Summary ToggleCB-1158 Phase I Data Accepted for an Oral Presentation at the ASCO Annual Meeting
03/29/17
Summary ToggleCalithera Biosciences to Present at the 16th Annual Needham Health Care Conference
03/28/17
Summary ToggleCalithera to Receive $12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study
03/27/17
Summary ToggleCalithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares
03/22/17
Summary ToggleCalithera Biosciences, Inc. Prices Public Offering of 6,830,000 shares of Common Stock
03/20/17
Summary ToggleCalithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock
03/16/17
Summary ToggleCalithera Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights
03/10/17
Summary ToggleCalithera Biosciences to Report Fourth Quarter and Year-End 2016 Financial Results on Thursday, March 16, 2017
03/01/17
Summary ToggleCalithera Biosciences to Present at Cowen and Company 37th Annual Health Care Conference
02/09/17
Summary ToggleCalithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February
01/30/17
Summary ToggleIncyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor